Association of British Clinical Diabetologists

Future ABCD nationwide audits

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above - centres contributing to the ABCD nationwide exenatide (left) and liraglutide (right) audits click to enlarge

 

Above: In real clinic practice in the UK, patients treated with exenatide or liraglutide had far worse glycaemic control and were much heavier than patients treated in clinical trials  click to enlarge

 

Above: Though the combination of exenatide and insulin was not licensed at the time of the ABCD nationwide exenatide audit, many contributors to the audit found benefits from the combination  click to enlarge

ABCD nationwide audit programme in the future

ABCD has learned from its
previous ABCD nationwide audits of GLP1 receptor agonists, SGLT2 inhibitors, insulin degludec, IDegLira and most recently the FreeStyle Libre. It has learned the best ways of undertaking successful nationwide audits. It has also realised how much clinically useful information can be obtained from the audit information to improve patient care. We are constantly considering possible future nationwide audits, both of new diabetes therapies and of devices. 2019 sees the launch of a nationwide semaglutide audit and an audit of testosterone in men with type two diabetes.

   Main ABCD homepage

ABCD canagliflozin audit

ABCD dapagliflozin audit

ABCD empagliflozin audit

ABCD FreeStyle Libre audit

 ABCD exenatide QW audit

ABCD semaglutide audit

ABCD IDegLira audit

ABCD degludec audit

ABCD liraglutide audit

ABCD exenatide audit

ABCD worldwide audits

Endobarrier worldwide registry

Contact us

     

Working to support high quality diabetes care in the UK